Unibest

Pharmaceutical intermediates

Asciminib hydrochloride Intermediates

6 pharmaceutical intermediates for Asciminib hydrochloride. Indication: Chronic Myelogenous Leukemia.

提交项目All intermediates

About Asciminib hydrochloride

Originator
Novartis Pharmaceuticals Corp
Indication
Chronic Myelogenous Leukemia
Approved Date
04/18/2024
NCE Patent
10/29/2026
DS/DP
05/13/2033

Available intermediates

6 intermediates currently listed for Asciminib hydrochloride. Request specifications, documentation or a quotation for any item below.

Asciminib hydrochloride intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
(R)-3-Pyrrolidinol2799-21-5//
Methyl 5-bromo-6-chloronicotinate78686-77-8//
1-(Tetrahydropyran-2-yl)-1H-pyrazole-5-boronic acid pinacol ester903550-26-5//
4-(Chlorodifluoromethoxy)aniline39065-95-7 //
5-Bromo-6-chloronicotinic acid29241-62-1//
4-[chloro(difluoro)methoxy]-{N}-methylaniline1217004-66-4//

Other programs under A

AbemaciclibAbrocitinibAcalabrutinibAdagrasibAfatinibAfoxolanerAlectinib HydrochlorideAlfacalcidol

Building toward Asciminib hydrochloride?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →